Table 3. Therapeutic efficacies stratified by treatment arms in IHCC with RAMlow and RAMhigh expression.
| C-GEMOX | GEMOX | p## | |
|---|---|---|---|
| RAMlow | N = 28 | N = 34 | |
| Disease control rate# | 68% (48–84) | 41% (25–59) | 0.044 |
| Median PFS (months) | 7.3 (5.6–10.9) | 4.9 (1.8–6.7) | 0.026 |
| Median OS (months) | 14.1 (10.1–20.0) | 9.6 (6.6–13.8) | 0.056 |
| RAMhigh | N=10 | N = 8 | |
| Disease control rate# | 40% (12–74) | 38% (9–76) | 1.000 |
| Median PFS (months) | 4.7 (1.5–8.6) | 4.5 (1.3–13.8) | 0.610 |
| Median OS (months) | 6.3 (2.6–12.0) | 5.2 (1.4–27.4) | 0.605 |
RAM, ROS1/ALK/c-MET; IHCC, intrahepatic cholangiocarcinoma; C-GEMOX, cetuximab plus gemcitabine and oxaplatin; PFS, progression-free survival; OS, overall survival.
#Disease control rate = complete response+ partial response+ stable disease >16 weeks.
##Disease control rates were compared using Fisher’s exact test, 2-tailed; PFS and OS were compared using log-rank test.